Abstract
Emphysematous pyelonephritis (EPN) is a rare and serious necrotizing infection that is potentially life-threatening. It has been seldom reported in kidney grafts and is usually caused by Gram-negative bacteria, with some case reports caused by anaerobic bacteria, and has been closely associated with poorly controlled diabetes mellitus (DM) and urinary tract structural abnormalities. There are no reports of EPN of fungal etiology in kidney grafts. We present a case of a 53-year-old kidney transplant recipient with a history of DM, active vesicoureteral reflux, and recurrent urinary tract infections who developed EPN in the kidney allograft caused by Candida glabrata, 3 weeks after starting treatment with empagliflozin, with an aggressive course that required urgent transplant nephrectomy.
References
1.
Arsene
C
, Saste
A
, Arul
S
, Mestrovich
J
, Kammo
R
, Elbashir
M
, et al A case series of emphysematous pyelonephritis
. Case Rep Med
. 2014
;2014
:1
–6
. 2.
Oliveira
CC
, Garcia
PD
, Viero
RM
. Emphysematous pyelonephritis in a transplanted kidney
. Autops Case Rep
. 2016 Dec
;6
(4
):41
–7
. 3.
Hildebrand
TS
, Nibbe
L
, Frei
U
, Schindler
R
. Bilateral emphysematous pyelonephritis caused by Candida infection
. Am J Kidney Dis
. 1999 Feb
;33
(2
):E10
.4.
Krishnasamy
PV
, Liby
C
. Emphysematous pyelonephritis caused by Candida tropicalis
. Am J Med
. 2010 Apr
;123
(4
):e7
–8
. 5.
Lotfali
E
, Abolghasemi
S
, Gatmirimotahhari
FS
, Alizadeh
M
, Arab-Mazar
Z
. Complicated bilateral fungal emphysematous pyelonephritis in a 55-year-old diabetic female: a case report and review of literature
. Curr Med Mycol
. 2018 Jun
;4
(2
):32
–5
. 6.
Ideguchi
S
, Yamamoto
K
, Ikeda
A
, Hashimoto
K
, Takazono
T
, Saijo
T
, et al A case of bilateral emphysematous pyelonephritis caused by Candida albicans
. J Infect Chemother
. 2019 Apr
;25
(4
):302
–6
. 7.
Seidenfeld
SM
, Lemaistre
CF
, Setiawan
H
, Munford
RS
. Emphysematous pyelonephritis caused by Candida tropicalis
. J Infect Dis
. 1982 Oct
;146
(4
):569
. 8.
Johnson
JR
, Ireton
RC
, Lipsky
BA
. Emphysematous pyelonephritis caused by Candida albicans
. J Urol
. 1986 Jul
;136
(1
):80
–2
.9.
Tanizawa
S
, Tahara
A
, Sakamoto
K
, Murata
A
, Inoue
E
, Ikuno
Y
, et al [A case of emphysematous pyelonephritis caused by Escherichia coli and Candida glabrata]
. Kansenshogaku Zasshi
. 1988 Aug
;62
(8
):739
–47
.10.
Jemal
S1
, Bahloul
A
, Jelidi
R
, Mhiri
MN
. Pyélonéphrite emphysémateuse à Candida albicans: à propos d’un nouveau cas
. J Urol
. 1994
;100
(3
):159
–62
.11.
Wu
VC
, Fang
CC
, Li
WY
, Hsueh
PR
, Chu
TS
. Candida tropicalis-associated bilateral renal papillary necrosis and emphysematous pyelonephritis
. Clin Nephrol
. 2004 Dec
;62
(6
):473
–5
.12.
Ahmad
M
. Emphysematous pyelonephritis due to Aspergillus fumigatus: a case report
. J Nephrol
. 2004 May–Jun
;17
(3
):446
–8
.13.
Kamaliah
MD
, Bhajan
MA
, Dzarr
GA
. Emphysematous pyelonephritis caused by Candida infection
. Southeast Asian J Trop Med Public Health
. 2005 May
;36
(3
):725
–7
.14.
Harrabi
H
, Marrakchi
C
, Daoud
E
, Elleuch
E
, Hammami
B
, Maâloul
I
, et al La pyélonéphrite emphysémateuse bilatérale à Candida glabrata: une entité exceptionnelle
. Nephrol Ther
. 2010 Nov
;6
(6
):541
–3
.15.
Ajili
F
, Labidi
J
, Ben Abdelhafith
N
, Battikh
R
, Othmani
S
. Candida albicans: une étiologie rare de pyélonéphrite emphysémateuse
. Med Mal Infect
. 2011 Oct
;41
(10
):560
–2
.16.
Bayrak
O
, Seçkiner
I
, Bulut
E
, Erturhan
SM
. Emphysematous pyelonephritis caused by Candida species: first case in the English literature
. Turkish J Urol
. 2012
;38
(4
): 244
–5
.17.
Bhat
RA
, Bashir
G
, Wani
M
, Lone
S
. Emphysematous pyelonephritis caused by Candida parapsilosis: an unknown etiological agent
. N Am J Med Sci
. 2012 Aug
;4
(8
):364
–6
. 18.
Alexander
S
, Varughese
S
, David
VG
, Kodgire
SV
, Mukha
RP
, Kekre
NS
, et al Extensive emphysematous pyelonephritis in a renal allograft treated conservatively: case report and review of the literature
. Transpl Infect Dis
. 2012 Dec
;14
(6
):E150
–5
. 19.
Huang
JJ
, Tseng
CC
. Emphysematous pyelonephritis: clinicoradiological classification, management, prognosis, and pathogenesis
. Arch Intern Med
. 2000 Mar 27
;160
(6
):797
–805
.20.
Al-Geizawi
SM
, Farney
AC
, Rogers
J
, Assimos
D
, Requarth
JA
, Doares
W
, et al Renal allograft failure due to emphysematous pyelonephritis: successful non-operative management and proposed new classification scheme based on literature review
. Transpl Infect Dis
. 2010 Dec
;12
(6
):543
–50
. 21.
Fisher
JF
, Sobel
JD
, Kauffman
CA
, Newman
CA
. Candida urinary tract infections: treatment
. Clin Infect Dis
. 2011 May 15
;52
(Suppl l–6
):S457
–66
.22.
Baran
J
Jr, Klauber
E
, Barczak
J
, Riederer
K
, Khatib
R
. Trends in antifungal susceptibility among Candida sp. urinary isolates from 1994 to 1998
. J Clin Microbiol
. 2000
;38
(2
):870
–1
.23.
Kurtz
MB
, Abruzzo
G
, Flattery
A
, Bartizal
K
, Marrinan
JA
, Li
W
, et al Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies
. Infect Immun
. 1996
;64
(8
):3244
–51
.24.
Sobel
JD
, Bradshaw
SK
, Lipka
CJ
, Kartsonis
NA
. Caspofungin in the treatment of symptomatic candiduria
. Clin Infect Dis
. 2007
; 44
(5
):e46
–9
. 25.
Lagrotteria
D
, Rotstein
C
, Lee
CH
. Treatment of candiduria with micafungin: a case series
. Can J Infect Dis Med Microbiol
. 2007
;18
(2
):149
–50
.26.
Gabardi
S
, Martin
S
, Sura
M
, Mohammed
A
, Golan
Y
. Micafungin treatment and eradication of candiduria among hospitalized patients
. Int Urol Nephrol
. 2016 Nov
;48
(11
):1881
–5
. 27.
Denis
B
, Chopin
D
, Piron
P
, Resche-Rigon
M
, Bretagne
S
, Gits-Muselli
M
, et al Candiduria in kidney transplant recipients: is antifungal therapy useful?
Mycoses
. 2018 May
;61
(5
):298
–304
. 28.
Zinman
B
, Wanner
C
, Lachin
JM
, Fitchett
D
, Bluhmki
E
, Hantel
S
, et al Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
. N Engl J Med
. 2015 Nov 26
;373
(22
):2117
–28
. 29.
Kufel
WD
, Scrimenti
A
, Steele
JM
. A case of septic shock due to Serratia marcescens pyelonephritis and bacteremia in a patient receiving empagliflozin
. J Pharm Pract
. 2017 Dec
;30
(6
):672
–5
. 30.
U.S. Food and Drug Administration
. FDA drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections
. [cited 2019 Jul 12] Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about.31.
Liu
J
, Li
L
, Li
S
, Jia
P
, Deng
K
, Chen
W
, et al Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis
. Sci Rep
. 2017 Dec
;7
(1
):2824
. 32.
Puckrin
R
, Saltiel
MP
, Reynier
P
, Azoulay
L
, Yu
OHY
, Filion
KB
. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials
. Acta Diabetol
. 2018 May
;55
(5
):503
–14
. 33.
Halden
TAS
, Kvitne
KE
, Midtvedt
K
, Rajakumar
L
, Robertsen
I
, Brox
J
, et al Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus
. Diabetes Care
. 2019 Jun
;42
(6
):1067
–74
. © 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
